Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 15-16/2021

23.02.2021 | commentary

Metformin recalls: regulatory background, concerns and challenges

verfasst von: DM Clinical Pharmacology Balakrishnan Sadasivam, MD Zeenat Fatima, MD, MSc Shubham Atal

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2021

Einloggen, um Zugang zu erhalten
share
TEILEN

Excerpt

Metformin is the most widely prescribed orally active anti-hyperglycemic drug in the world today, which was discovered way back in the seventeenth century and launched in the twentieth century [ 1]. It is the first choice anti-hyperglycemic for type 2 diabetes mellitus (T2DM) in combination with lifestyle intervention unless there are contraindications or intolerability, the maximum recommended dose being 2500 mg [ 2]. It is the only oral anti-hyperglycemic approved for T2DM in children and prediabetes [ 3]. With well-established efficacy and safety, it is inexpensive and may reduce risk of cardiovascular events and death [ 4]. It is also recommended as an alternative treatment for infertility due to polycystic ovarian syndrome in selected cases [ 5]. Several studies have led to its off-label use in fatty liver disease, obesity, thyroid disorders, dementia prevention and cancer prevention [ 5, 6]. Metformin is available as immediate-release (IR) and extended-release (ER/XR) formulations. Metformin IR and metformin XR were patented by Bristol-Meyers Squibb in 1998 and 2000 under the name Glucophage and Glucophage XR, respectively. Subsequently, after the end of patent protection, both the formulations are now manufactured as a generic by multiple pharmaceutical companies. …

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
1.
Zurück zum Zitat Patade GR, Marita AR. Metformin: a journey from countryside to the bedside. J Obes Metab Res. 2014;1:127–30. CrossRef Patade GR, Marita AR. Metformin: a journey from countryside to the bedside. J Obes Metab Res. 2014;1:127–30. CrossRef
2.
Zurück zum Zitat American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes 2019. Diabetes Care. 2019;42:90–S102. CrossRef American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes 2019. Diabetes Care. 2019;42:90–S102. CrossRef
3.
Zurück zum Zitat Khokhar A, Umpaichitra V, Chin VL, Perez-Colon S. Metformin use in children and adolescents with prediabetes. Pediatr Clin North Am. 2017;64:1341–53. CrossRef Khokhar A, Umpaichitra V, Chin VL, Perez-Colon S. Metformin use in children and adolescents with prediabetes. Pediatr Clin North Am. 2017;64:1341–53. CrossRef
4.
Zurück zum Zitat Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89. CrossRef Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89. CrossRef
5.
Zurück zum Zitat Wang YW, He SJ, Feng X, Cheng J, Luo YT, Tian L, et al. Metformin: a review of its potential indications. Drug Des Devel Ther. 2017;11:2421–9. CrossRef Wang YW, He SJ, Feng X, Cheng J, Luo YT, Tian L, et al. Metformin: a review of its potential indications. Drug Des Devel Ther. 2017;11:2421–9. CrossRef
6.
Zurück zum Zitat Abdelgadir E, Ali R, Rashid F, Bashier A. Effect of metformin on different non-diabetes related conditions, a special focus on malignant conditions: review of literature. J Clin Med Res. 2017;9(5):388–95. CrossRef Abdelgadir E, Ali R, Rashid F, Bashier A. Effect of metformin on different non-diabetes related conditions, a special focus on malignant conditions: review of literature. J Clin Med Res. 2017;9(5):388–95. CrossRef
11.
Zurück zum Zitat International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Overall evaluations of carcinogenicity: an updating of IARC Monographs Volumes 1–42. supplement no 7. Lyon: International Agency for Research on Cancer; 1987. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Overall evaluations of carcinogenicity: an updating of IARC Monographs Volumes 1–42. supplement no 7. Lyon: International Agency for Research on Cancer; 1987.
12.
Zurück zum Zitat Argus MF, Hoch-Ligeti C. Comparative study of the carcinogenic activity of nitrosamines. J Natl Cancer Inst. 1961;27:695–709. PubMed Argus MF, Hoch-Ligeti C. Comparative study of the carcinogenic activity of nitrosamines. J Natl Cancer Inst. 1961;27:695–709. PubMed
Metadaten
Titel
Metformin recalls: regulatory background, concerns and challenges
verfasst von
DM Clinical Pharmacology Balakrishnan Sadasivam
MD Zeenat Fatima
MD, MSc Shubham Atal
Publikationsdatum
23.02.2021
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 15-16/2021
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-021-01822-1